TABLE 2.
Demographics and baseline characteristics of participants in the multiple‐rising dose study
| Placebo (n = 12) a | BI 705564 | ||||||
|---|---|---|---|---|---|---|---|
| 10 mg (n = 8) | 20 mg (n = 8) | 40 mg (n = 8) | 60 mg (n = 8) | 80 mg (n = 8) | 40 mg SPTG (n = 8) | ||
| Age (y), median (range) | 38 (27–50) | 34 (23–48) | 46 (35–51) | 32 (21–47) | 38 (28–48) | 46 (26–51) | 25 (18–49) |
| Height (cm), mean (SD) | 181 (10) | 176 (4) | 182 (4) | 178 (4) | 177 (5) | 178 (7) | 183 (8) |
| BMI (kg/m2), mean (SD) | 26 (3) | 25 (3) | 25 (2) | 23 (3) | 26 (2) | 26 (3) | 26 (3) |
a
Includes all participants who received placebo in the trial.
BMI, body mass index; SD, standard deviation; SPTG, skin prick test group.